Developments in the treatment of uveitis.
Uveitis remains a challenging field to the ophthalmologist as the disease causes significant morbidity and the use of traditional forms of treatment is restricted by limited effectiveness and considerable side effects. This article explores new agents used in the treatment of uveitis as well as the potential of agents used successfully in experimental uveitis. This paper also reviews agents in use for a long time but now used in novel ways.
Lightman
Susan
S
Dept. of Clinical Ophthalmology, Institute of Ophthalmology, Moorfields Eye Hospital, City Road, London, UK. s.lightman@ucl.ac.uk
Kok
Howesen
H
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology
D000276:Adjuvants, Immunologic; D000305:Adrenal Cortex Hormones; D000963:Antimetabolites; D018906:Antineoplastic Agents, Alkylating; D016207:Cytokines; D004791:Enzyme Inhibitors; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D002699:Chlorambucil